Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease

Movement Disorders

Volumn 23, Issue 10, 2008, Pages 1458-1461

  Müller, Thomas ^a,b   Woitalla, Dirk ^b   Goetze, Oliver ^b,c   Erdmann, Christoph ^b  

^a St Joseph Hospital   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Absorption; Entacapone; Levodopa; Parkinson's disease

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; OCTANOIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SOLUBILITY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL MUCOSA; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; STOMACH EMPTYING;

ADULT; AGED; ANTIPARKINSON AGENTS; BREATH TESTS; CARBIDOPA; CARBON ISOTOPES; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; GASTRIC EMPTYING; HUMANS; INTESTINAL ABSORPTION; LEVODOPA; MALE; MIDDLE AGED; NITRILES; OCTANOIC ACIDS; PARKINSON DISEASE; SOLUBILITY;

EID: 52649150948     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22176     Document Type: Article

References (9)

1. Kortejarvi H, Urtti A, Yliperttula M. Pharmacokinetic simulation of biowaiver criteria: The effects of gastric emptying, dissolution, absorption and elimination rates. Eur J Pharma Sci 2007;30:155-166.
2. Forsberg MM, Huotari M, Savolainen J, Mannisto PT. The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration. Eur J Pharma Sci 2005;24:503-511.
3. Goetze O, Wieczorek J, Müller T, Przuntek H, Schmidt WE, Woitalla D. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test. Neurosci Lett 2005;375:170-173.
4. Lennernäs H. Modeling gastrointestinal dirug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Curr Drug Metab 2007;8:1389-2002.
5. +-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol 2007;92:603-619.
6. Müller T, Erdmann C, Bremen D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 2006;29:61-67.
7. Müller T, Erdmann C, Muhlack S, et al. Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease. J Neural Transm 2006;113:1441-1448.
8. Woitalla D, Goetze O, Kim JI, et al. Levodopa availability improves with progression of Parkinson's disease. J Neurol 2006;253:1221-1226.
9. Goetze O, Nikodem AB, Wiezcorek J, et al. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil 2006; 18:369-375.